RhumbLine Advisers’s Larimar Therapeutics LRMR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $195K | Buy |
67,358
+2,340
| +4% | +$6.76K | ﹤0.01% | 3244 |
|
|
2025
Q1 | $140K | Buy |
65,018
+8,818
| +16% | +$19K | ﹤0.01% | 3282 |
|
|
2024
Q4 | $217K | Buy |
56,200
+519
| +0.9% | +$2.01K | ﹤0.01% | 3148 |
|
|
2024
Q3 | $365K | Buy |
55,681
+745
| +1% | +$4.88K | ﹤0.01% | 2916 |
|
|
2024
Q2 | $398K | Buy |
54,936
+23,475
| +75% | +$170K | ﹤0.01% | 2831 |
|
|
2024
Q1 | $239K | Buy |
31,461
+3,139
| +11% | +$23.8K | ﹤0.01% | 3090 |
|
|
2023
Q4 | $129K | Sell |
28,322
-614
| -2% | -$2.79K | ﹤0.01% | 3363 |
|
|
2023
Q3 | $114K | Buy |
28,936
+2,432
| +9% | +$9.61K | ﹤0.01% | 3420 |
|
|
2023
Q2 | $83K | Buy |
+26,504
| New | +$83K | ﹤0.01% | 3569 |
|
|
2019
Q2 | – | Sell |
-3,226
| Closed | -$106K | – | 2995 |
|
|
2019
Q1 | $106K | Sell |
3,226
-57
| -2% | -$1.87K | ﹤0.01% | 2851 |
|
|
2018
Q4 | $195K | Buy |
3,283
+1,314
| +67% | +$78K | ﹤0.01% | 2741 |
|
|
2018
Q3 | $276K | Buy |
1,969
+225
| +13% | +$31.5K | ﹤0.01% | 2557 |
|
|
2018
Q2 | $214K | Buy |
+1,744
| New | +$214K | ﹤0.01% | 2703 |
|
|
2017
Q2 | – | Sell |
-2,325
| Closed | -$130K | – | 2942 |
|
|
2017
Q1 | $130K | Buy |
2,325
+551
| +31% | +$30.8K | ﹤0.01% | 2747 |
|
|
2016
Q4 | $68K | Sell |
1,774
-1,142
| -39% | -$43.8K | ﹤0.01% | 2814 |
|
|
2016
Q3 | $116K | Buy |
2,916
+25
| +0.9% | +$995 | ﹤0.01% | 2795 |
|
|
2016
Q2 | $208K | Buy |
2,891
+1,467
| +103% | +$106K | ﹤0.01% | 2721 |
|
|
2016
Q1 | $114K | Hold |
1,424
| – | – | ﹤0.01% | 2870 |
|
|
2015
Q4 | $107K | Buy |
1,424
+208
| +17% | +$15.6K | ﹤0.01% | 2944 |
|
|
2015
Q3 | $466K | Buy |
1,216
+56
| +5% | +$21.5K | ﹤0.01% | 2272 |
|
|
2015
Q2 | $482K | Buy |
1,160
+682
| +143% | +$283K | ﹤0.01% | 2357 |
|
|
2015
Q1 | $227K | Buy |
+478
| New | +$227K | ﹤0.01% | 2768 |
|